Regulation - Asia-Pacific, Cardio-vascular

Filter

Popular Filters

Daiichi Sankyo submits edoxaban application to the EMA for stroke prevention

Daiichi Sankyo submits edoxaban application to the EMA for stroke prevention

08-01-2014

Japanese drug major Daiichi Sankyo (TYO: 4568) has submitted a Marketing Authorization Application to…

Asia-PacificCardio-vascularDaiichi SankyoedoxabanPharmaceuticalRegulation

Japanese lawmakers are stepping in to Diovan investigation

07-10-2013

Members of Japan’s Diet (Congressmen) have formed a bipartisan study group to examine Swiss drug major…

Asia-PacificCardio-vascularDiovanNovartisPharmaceuticalPoliticsRegulationResearch

Novartis under investigation for manipulating data in Japanese clinical trials

Novartis under investigation for manipulating data in Japanese clinical trials

27-09-2013

Swiss drug major Novartis has said it regrets the inconvenience caused by its investigator-initiated…

Asia-PacificCardio-vascularLegalNovartisPharmaceuticalRegulationvalsartan

Daiichi Sankyo files for Japanese approval of Prasugrel

18-06-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that it has submitted a New Drug Application to the…

Asia-PacificCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelRegulation

New Zealand to fund AstraZeneca's Brilinta for acute coronary syndromes

10-06-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, says it has reached an agreement with the local…

Asia-PacificAstraZenecaBrilintaCardio-vascularPharmaceuticalPricingRegulation

Daiichi Sankyo updates on PRASFIT-Elective study, NDA filing

14-03-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that the follow-up period for the Phase III PRASFIT-Elective…

Asia-PacificAspirinCardio-vascularDaiichi SankyoEffientPharmaceuticalprasugrelRegulationResearch

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis

27-12-2012

Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Australian review finds more work needed on new anticoagulants

19-12-2012

A report into anticoagulation therapies released yesterday by Australian Minister for Health Tanya Plibersek…

Asia-PacificBoehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulation

Daiichi Sankyo to file prasugrel in Japan next year, following strong results

25-09-2012

Japanese drug major Daiichi Sankyo (TYO: 4568) has announced data from the PRASFIT-ACS study, a double-blind…

Asia-PacificCardio-vascularDaiichi SankyoPharmaceuticalprasugrelRegulationResearch

J&J's Janssen files Xarelto with FDA for new indication; buys Chinese firm

03-05-2012

US health care major Johnson & Johnson's (NYSE: JNJ) subsidiary Janssen Research & Development says it…

Asia-PacificBayerBioseal BiotechBiotechnologyCardio-vascularJanssenJohnson & JohnsonMergers & AcquisitionsNorth AmericaPharmaceuticalRegulationXarelto

New Zealand approves Effient listing for clopidogrel-allergic patients

19-03-2012

The Pharmaceutical Management Agency of New Zealand, PHARMAC, has announced reaching agreement with US…

Asia-PacificCardio-vascularEffientEli LillyPharmaceuticalPricingRegulation

Sihuan Pharma heart drug IND accepted in China

12-03-2012

Leading China-based cardio-cerebral vascular drug firm Sihuan Pharmaceutical Holdings (HKEx: 0460) says…

Asia-PacificCardio-vascularMarkets & MarketingPharmaceuticalRegulationSihuan Pharmaceuticaltylerdipine

Back to top